The following Independence Blue Cross and Independence Administrators policies went into effect on January 1, 2023:
Commercial policies:
- 00.10.41k: Telemedicine
- 05.00.69c: Home-Use Light Box Therapy for the Treatment of Seasonal Affective Disorder (SAD)
- 05.00.80c: Cranial Electrotherapy Stimulation
- 06.02.30g: Pharmacogenetic Testing to Determine Drug Sensitivity
- 06.02.44p: Presumptive and Definitive Drug Testing in Substance Abuse and Pain Management Treatments
- 06.02.55a: Therapeutic Drug Monitoring for Antidepressants, Antipsychotics, or Antiepileptics
- 07.03.07h: Medical Evaluation and Management for Attention-Deficit Hyperactivity Disorder (ADHD)
- 07.03.22e: Transcranial Magnetic Stimulation
- 08.01.37b: Maintenance Treatment of Opioid or Alcohol Dependence Disorder
- 08.01.80a: Intravenous Ketamine (Ketalar®) and Intranasal Esketamine (Spravato®)
- 11.15.16r: Vagus Nerve Stimulation (VNS)
- 11.15.20q: Deep Brain Stimulation (DBS)
- 12.01.01bg: Experimental/Investigational
- 12.04.04b: Acute Care Facility Inpatient Transfers
- 14.00.01: Electroconvulsive therapy (ECT)
- 14.00.02: Psychological Testing
- 14.00.03: Applied Behavioral Analysis (ABA) for the Treatment of Autism Spectrum Disorder (ASD)
Medicare Advantage policies:
- MA00.005af: Experimental/Investigational
- MA05.022a: Home-Use Light Box Therapy for the Treatment of Seasonal Affective Disorder (SAD)
- MA05.066c: Cranial Electrotherapy Stimulation
- MA06.025p: Presumptive and Definitive Drug Testing in Substance Abuse and Pain Management Treatments
- MA06.029a: Therapeutic Drug Monitoring for Antidepressants, Antipsychotics, or Antiepileptics
- MA07.035d: Transcranial Magnetic Stimulation
- MA08.137a: Intravenous Ketamine (Ketalar®) and Intranasal Esketamine (Spravato®)
- MA11.005e: Deep Brain Stimulation (DBS)
- MA11.019h: Vagus Nerve Stimulation (VNS)
- MA12.003b: Acute Care Facility Inpatient Transfers
- MA14.001: Electroconvulsive therapy (ECT)
- MA14.002: Psychological Testing
For more information, please refer to the Commercial and Medicare Advantage policies, which were published on January 1, 2023.